Gemma Biotherapeutics, a Philadelphia, PA-based therapeutics company, closed a $34m seed funding.
The round was co-led by Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital, with additional backing from Savanne Life Sciences.
The company intends to use the funds to accelerate operational expansion and innovative gene therapy programs.
Founded by Dr. Jim Wilson, GEMMABio is at the forefront of advancing gene therapy research, with a focus on accelerating the development and delivery of life-changing therapies to patients worldwide.
Since its launch on October 1, 2024, the company has several active programs, including a recently announced collaboration with Fiocruz, the main supplier of immunobiologics, biopharmaceuticals and diagnostics to the Brazilian Ministry of Health.
FinSMEs
24/12/2024